Erratum: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (The Lancet (2012) 379(9835) (2439–2448) (S0140673612609179) (10.1016/S0140-6736(12)60917-9));Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

The Lancet

Volumn 379, Issue 9835, 2012, Pages 2439-2448

  Sax, Paul E ^a   DeJesus, Edwin ^b   Mills, Anthony ^c   Zolopa, Andrew ^d   Cohen, Calvin ^e   Wohl, David ^f   Gallant, Joel E ^f   Liu, Hui C ^g   Zhong, Lijie ^h   Yale, Kitty ^h   White, Kirsten ^h   Kearney, Brian P ^h   Szwarcberg, Javier ^h   Quirk, Erin ^h   Cheng, Andrew K ^h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Anthony Mills MD   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Boston Community Research Initiative of New England   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR; CREATININE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMAL DREAMING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

EID: 84862876886     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61410-X     Document Type: Erratum

References (35)

1. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011; Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf (accessed Feb 22, 2012).
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adults with HIV infection; 2010 Recommendations of the International AIDS Society-USA Panel. JAMA 2010; 304: 321-33.
3. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine and efavirenz compared with zidovudine/ lamivudine and efavirenz in treatment-naive patients; 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78. (Pubitemid 351619372)
4. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV therapy. N Engl J Med 2009; 361: 2230-40.
5. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial. Lancet 2011; 378: 229-37.
6. Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
7. McKinnell JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naive patients in the United States. AIDS Patient Care STDs 2010; 24: 79-85.
8. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
9. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
10. ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets. US prescribing information. Gilead Sciences and Bristol-Myers Squibb. September 2011.
11. Ocfemia CB, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, USA; March 5-8, 2012. Abstract 730.
12. Kim D, Wheeler W, Ziebell R, et al. Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1 infected persons, United States, 2007. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; Feb 16-19, 2010. Abstract 580.
13. COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. US prescribing information. Gilead Sciences. August 2011.
14. Eviplera 200 mg/25mg/245mg film-coated tablets: summary of product characteristics. Gilead Sciences. Cambridge, UK. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/002312/WC500118802.pdf (accessed June 14, 2012).
15. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-74.
16. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43: 1-5. (Pubitemid 44306480)
17. Molina JM, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12: 27-35.
18. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7-12.
19. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. 2002. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf (accessed April 20, 2012) .
20. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical Data Analysis. In: Berry DA, ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker, 1989: 414-21.
21. Gallant J, DeJesus E, Arribas JR, et al. Tenofovir DR, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60. (Pubitemid 43113030)
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
23. German P, Lui C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17-20, 2011. Abstract H2-804.
24. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with atazanavir plus fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011; 25: 1881-86.
25. DeJesus E, Rockstroh JK, Henry K, et al, for the GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
26. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. JAIDS 2011; 55: 39-48.
27. Daar ES, Tierney C, Fischl M, et al. ACTG 5202: final results of abacavir/lamivudine (ABC/3TC) or tenofovir DF/emtricitabine (TDF/FTC) with either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in treatment-naive HIV-infected patients. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; Feb 16-19, 2010. 59LB.
28. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63. (Pubitemid 38496486)
29. Haubrich RH, Riddler SA, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS 2011; 25: 2269-78.
30. Llibre JM, Arribas JR, Domingo P, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011; 25: 1683-90.
31. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDs 2010; 24: 87-96.
32. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
33. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24: 2835-40.
34. Cohen C, Davis KL, Meyers J. Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population with HIV. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17-20, 2011. Abstract H2-791.
35. Sax PE, Meyers J, Mugavero M, Davis KL. Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012; 7: e31591.